We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-9.88%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$143M
Cap. Flow
+$317M
Cap. Flow %
20.31%
Top 10 Hldgs %
50.44%
Holding
68
New
13
Increased
28
Reduced
8
Closed
16

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.6M
2
FATE icon
Fate Therapeutics
FATE
+$61.3M
3
AGEN
Agenus
AGEN
+$38.5M
4
BCYC
Bicycle Therapeutics
BCYC
+$35.3M
5
NVCR icon
NovoCure
NVCR
+$33.1M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$23.8M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$17.1M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$11.9M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.24%
2 Real Estate 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVCR icon
1
NovoCure
NVCR
$1.73B
$82.8M 5.31%
1,000,000
+450,000
+82% +$33.1M
BCYC
2
Bicycle Therapeutics
BCYC
$269M
$81.4M 5.22%
1,855,993
+755,993
+69% +$35.3M
TVTX icon
3
Travere Therapeutics
TVTX
$5.2B
$80.8M 5.18%
3,134,503
+684,503
+28% +$18.2M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$80.5M 5.16%
517,051
+17,051
+3% +$2.47M
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$79.8M 5.12%
2,304,683
+304,683
+15% +$9.11M
FATE icon
6
Fate Therapeutics
FATE
$286M
$77.5M 4.97%
2,000,000
+1,581,963
+378% +$61.3M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$10.8B
$77.1M 4.95%
786,000
+286,000
+57% +$24.1M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$75.7M 4.86%
4,500,000
+500,000
+13% +$7.39M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$27.5B
$75.7M 4.86%
+463,663
New +$70.6M
KROS icon
10
Keros Therapeutics
KROS
$199M
$75.1M 4.81%
1,380,306
+80,306
+6% +$4.12M
KURA icon
11
Kura Oncology
KURA
$800M
$54.9M 3.52%
3,412,000
+862,000
+34% +$12.4M
KDNY
12
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$49.1M 3.15%
3,000,000
+579,498
+24% +$7.88M
BEAM icon
13
Beam Therapeutics
BEAM
$2.63B
$43.8M 2.81%
763,750
+63,750
+9% +$4.18M
IMVT icon
14
Immunovant
IMVT
$7.93B
$39.8M 2.55%
7,224,613
+2,449,613
+51% +$15.3M
RPTX
15
DELISTED
Repare Therapeutics
RPTX
$37.9M 2.43%
2,664,017
+564,017
+27% +$8.36M
FDMT icon
16
4D Molecular Therapeutics
FDMT
$532M
$37M 2.37%
2,448,200
+548,200
+29% +$8.61M
AGEN
17
Agenus
AGEN
$312M
$34.4M 2.21%
+713,223
New +$38.5M
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.84B
$33.8M 2.17%
1,541,715
-358,285
-19% -$7.25M
DYN icon
19
Dyne Therapeutics
DYN
$4.7B
$33.7M 2.16%
3,500,000
+1,207,750
+53% +$10.3M
JNCE
20
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$28.9M 1.85%
4,259,653
+259,653
+6% +$1.85M
ESPR
21
DELISTED
Esperion Therapeutics
ESPR
$27.8M 1.79%
6,000,000
+358,332
+6% +$1.54M
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$25.5M 1.64%
1,729,757
+229,757
+15% +$3.3M
NKTX icon
23
Nkarta
NKTX
$150M
$24.1M 1.54%
2,113,795
+849,369
+67% +$9.09M
DICE
24
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$23.9M 1.53%
1,250,000
-91,004
-7% -$1.62M
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$22.3M 1.43%
675,000
+175,000
+35% +$6.58M
1
2 3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Deep Track Capital held 68 positions worth $1.56B, up 10% from $1.42B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deep Track Capital deployed $317M of net new capital in Q1 2022, opening 13 new positions and adding to 28 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 463,663 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Verve Therapeutics, an estimated $11.4M trimmed.

  • Deep Track Capital's largest Q1 2022 buy was Alnylam Pharmaceuticals: 463,663 shares worth $75.7M.
  • Deep Track Capital added most to Fate Therapeutics in Q1 2022, an estimated $61.3M increase.
  • Deep Track Capital's biggest Q1 2022 reduction was Verve Therapeutics, cutting an estimated $11.4M.
  • Deep Track Capital fully exited Avidity Biosciences in Q1 2022, selling an estimated $23.8M.
  • Deep Track Capital's ten largest holdings make up 50% of its $1.56B portfolio in Q1 2022.
  • Deep Track Capital opened 13 new positions and closed 16 in Q1 2022.
  • Deep Track Capital's portfolio value rose 10% quarter-over-quarter to $1.56B.

Based on Deep Track Capital's 13F filing for Q1 2022, filed 16 May 2022.